A brave new framework for glioma drug development

Kelly M. Hotchkiss; Philipp Karschnia; Karisa C. Schreck; Marjolein Geurts; Timothy F. Cloughesy; Jason Huse; Elizabeth S. Duke; Justin Lathia; David M. Ashley; Edjah K. Nduom; Georgina Long; Kirit Singh; Anthony Chalmers; Manmeet S. Ahluwalia; Amy Heimberger; Stephen Bagley; Tomoki Todo; Roel Verhaak; Patrick D. Kelly; Shawn Hervey-Jumper; John de Groot; Anoop Patel; Peter Fecci; Ian Parney; Victoria Wykes; Colin Watts; Terry C. Burns; Nader Sanai; Matthias Preusser; Joerg Christian Tonn; Katharine J. Drummond; Michael Platten; Sunit Das; Kirk Tanner; Michael A. Vogelbaum; Michael Weller; James R. Whittle; Mitchel S. Berger; Mustafa Khasraw

doi:10.1016/S1470-2045(24)00190-6

A brave new framework for glioma drug development

Kelly M. Hotchkiss, Philipp Karschnia, Karisa C. Schreck, Marjolein Geurts, Timothy F. Cloughesy, Jason Huse, Elizabeth S. Duke, Justin Lathia, David M. Ashley, Edjah K. Nduom, Georgina Long, Kirit Singh, Anthony Chalmers, Manmeet S. Ahluwalia, Amy Heimberger, Stephen Bagley, Tomoki Todo, Roel Verhaak, Patrick D. Kelly, Shawn Hervey-JumperJohn de Groot, Anoop Patel, Peter Fecci, Ian Parney, Victoria Wykes, Colin Watts, Terry C. Burns, Nader Sanai, Matthias Preusser, Joerg Christian Tonn, Katharine J. Drummond, Michael Platten, Sunit Das, Kirk Tanner, Michael A. Vogelbaum, Michael Weller, James R. Whittle, Mitchel S. Berger, Mustafa Khasraw^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic › peer-review

3 Citations (Scopus)

Abstract

Patients with brain tumours are motivated to participate in clinical trials involving repeat tissue sampling. Normalising the use of neoadjuvant and staged surgical trials necessitates collaboration among patients, regulatory agencies, and researchers. Initial and repetitive tissue sampling plays a crucial role in enhancing our understanding of resistance mechanisms and vulnerabilities in brain tumour therapy. Standardising biopsy techniques and ensuring technical uniformity across institutions are vital for effective interinstitutional collaboration. Although liquid biopsy technologies hold promise, they are not yet ready to replace tissue analysis. Clear communication about the risks and benefits of biopsies is essential, particularly regarding potential postoperative deficits. Changes in mindset and neurosurgical culture are imperative to achieve much needed breakthroughs in the development of new, effective therapies for brain tumours.

Original language	English
Pages (from-to)	e512-e519
Journal	The Lancet Oncology
Volume	25
Issue number	10
DOIs	https://doi.org/10.1016/S1470-2045(24)00190-6
Publication status	Published - Oct 2024

Bibliographical note

Publisher Copyright:
© 2024 Elsevier Ltd

Access to Document

10.1016/S1470-2045(24)00190-6

A brave new framework for glioma drug developmentFinal published version, 449 KBLicence: Article 25fa Dutch Copyright Act

Cite this

Hotchkiss, K. M., Karschnia, P., Schreck, K. C., Geurts, M., Cloughesy, T. F., Huse, J., Duke, E. S., Lathia, J., Ashley, D. M., Nduom, E. K., Long, G., Singh, K., Chalmers, A., Ahluwalia, M. S., Heimberger, A., Bagley, S., Todo, T., Verhaak, R., Kelly, P. D., ... Khasraw, M. (2024). A brave new framework for glioma drug development. The Lancet Oncology, 25(10), e512-e519. https://doi.org/10.1016/S1470-2045(24)00190-6

@article{bd34f33ef60c4ea58df969ae22d4f36f,

title = "A brave new framework for glioma drug development",

abstract = "Patients with brain tumours are motivated to participate in clinical trials involving repeat tissue sampling. Normalising the use of neoadjuvant and staged surgical trials necessitates collaboration among patients, regulatory agencies, and researchers. Initial and repetitive tissue sampling plays a crucial role in enhancing our understanding of resistance mechanisms and vulnerabilities in brain tumour therapy. Standardising biopsy techniques and ensuring technical uniformity across institutions are vital for effective interinstitutional collaboration. Although liquid biopsy technologies hold promise, they are not yet ready to replace tissue analysis. Clear communication about the risks and benefits of biopsies is essential, particularly regarding potential postoperative deficits. Changes in mindset and neurosurgical culture are imperative to achieve much needed breakthroughs in the development of new, effective therapies for brain tumours.",

author = "Hotchkiss, {Kelly M.} and Philipp Karschnia and Schreck, {Karisa C.} and Marjolein Geurts and Cloughesy, {Timothy F.} and Jason Huse and Duke, {Elizabeth S.} and Justin Lathia and Ashley, {David M.} and Nduom, {Edjah K.} and Georgina Long and Kirit Singh and Anthony Chalmers and Ahluwalia, {Manmeet S.} and Amy Heimberger and Stephen Bagley and Tomoki Todo and Roel Verhaak and Kelly, {Patrick D.} and Shawn Hervey-Jumper and {de Groot}, John and Anoop Patel and Peter Fecci and Ian Parney and Victoria Wykes and Colin Watts and Burns, {Terry C.} and Nader Sanai and Matthias Preusser and Tonn, {Joerg Christian} and Drummond, {Katharine J.} and Michael Platten and Sunit Das and Kirk Tanner and Vogelbaum, {Michael A.} and Michael Weller and Whittle, {James R.} and Berger, {Mitchel S.} and Mustafa Khasraw",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Ltd",

year = "2024",

month = oct,

doi = "10.1016/S1470-2045(24)00190-6",

language = "English",

volume = "25",

pages = "e512--e519",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "10",

}

Hotchkiss, KM, Karschnia, P, Schreck, KC, Geurts, M, Cloughesy, TF, Huse, J, Duke, ES, Lathia, J, Ashley, DM, Nduom, EK, Long, G, Singh, K, Chalmers, A, Ahluwalia, MS, Heimberger, A, Bagley, S, Todo, T, Verhaak, R, Kelly, PD, Hervey-Jumper, S, de Groot, J, Patel, A, Fecci, P, Parney, I, Wykes, V, Watts, C, Burns, TC, Sanai, N, Preusser, M, Tonn, JC, Drummond, KJ, Platten, M, Das, S, Tanner, K, Vogelbaum, MA, Weller, M, Whittle, JR, Berger, MS & Khasraw, M 2024, 'A brave new framework for glioma drug development', The Lancet Oncology, vol. 25, no. 10, pp. e512-e519. https://doi.org/10.1016/S1470-2045(24)00190-6

TY - JOUR

T1 - A brave new framework for glioma drug development

AU - Hotchkiss, Kelly M.

AU - Karschnia, Philipp

AU - Schreck, Karisa C.

AU - Geurts, Marjolein

AU - Cloughesy, Timothy F.

AU - Huse, Jason

AU - Duke, Elizabeth S.

AU - Lathia, Justin

AU - Ashley, David M.

AU - Nduom, Edjah K.

AU - Long, Georgina

AU - Singh, Kirit

AU - Chalmers, Anthony

AU - Ahluwalia, Manmeet S.

AU - Heimberger, Amy

AU - Bagley, Stephen

AU - Todo, Tomoki

AU - Verhaak, Roel

AU - Kelly, Patrick D.

AU - Hervey-Jumper, Shawn

AU - de Groot, John

AU - Patel, Anoop

AU - Fecci, Peter

AU - Parney, Ian

AU - Wykes, Victoria

AU - Watts, Colin

AU - Burns, Terry C.

AU - Sanai, Nader

AU - Preusser, Matthias

AU - Tonn, Joerg Christian

AU - Drummond, Katharine J.

AU - Platten, Michael

AU - Das, Sunit

AU - Tanner, Kirk

AU - Vogelbaum, Michael A.

AU - Weller, Michael

AU - Whittle, James R.

AU - Berger, Mitchel S.

AU - Khasraw, Mustafa

PY - 2024/10

Y1 - 2024/10

N2 - Patients with brain tumours are motivated to participate in clinical trials involving repeat tissue sampling. Normalising the use of neoadjuvant and staged surgical trials necessitates collaboration among patients, regulatory agencies, and researchers. Initial and repetitive tissue sampling plays a crucial role in enhancing our understanding of resistance mechanisms and vulnerabilities in brain tumour therapy. Standardising biopsy techniques and ensuring technical uniformity across institutions are vital for effective interinstitutional collaboration. Although liquid biopsy technologies hold promise, they are not yet ready to replace tissue analysis. Clear communication about the risks and benefits of biopsies is essential, particularly regarding potential postoperative deficits. Changes in mindset and neurosurgical culture are imperative to achieve much needed breakthroughs in the development of new, effective therapies for brain tumours.

AB - Patients with brain tumours are motivated to participate in clinical trials involving repeat tissue sampling. Normalising the use of neoadjuvant and staged surgical trials necessitates collaboration among patients, regulatory agencies, and researchers. Initial and repetitive tissue sampling plays a crucial role in enhancing our understanding of resistance mechanisms and vulnerabilities in brain tumour therapy. Standardising biopsy techniques and ensuring technical uniformity across institutions are vital for effective interinstitutional collaboration. Although liquid biopsy technologies hold promise, they are not yet ready to replace tissue analysis. Clear communication about the risks and benefits of biopsies is essential, particularly regarding potential postoperative deficits. Changes in mindset and neurosurgical culture are imperative to achieve much needed breakthroughs in the development of new, effective therapies for brain tumours.

UR - http://www.scopus.com/inward/record.url?scp=85205258856&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(24)00190-6

DO - 10.1016/S1470-2045(24)00190-6

M3 - Review article

C2 - 39362262

AN - SCOPUS:85205258856

SN - 1470-2045

VL - 25

SP - e512-e519

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 10

ER -

A brave new framework for glioma drug development

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this